Marshall Wace, LLP Theravance Biopharma, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 150,060 shares of TBPH stock, worth $1.41 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150,060
Previous 297,499
49.56%
Holding current value
$1.41 Million
Previous $2.52 Million
52.06%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding TBPH
# of Institutions
122Shares Held
47.3MCall Options Held
200Put Options Held
12.8K-
Madison Avenue Partners, LP New York, NY9.51MShares$89.6 Million9.44% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$70.2 Million1.94% of portfolio
-
Newtyn Management, LLC New York, NY4.5MShares$42.4 Million6.4% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$35.6 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$26 Million1.95% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $629M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...